Stomach-Draining Device Makes Play For Obesity Surgery Patients
This article was originally published in The Gray Sheet
Approved as a long-term treatment option for obese patients with a body-mass index of 35 to 55, Aspire Bariatrics is positioning its AspireAssist device as a less-invasive alternative to bariatric surgery in the population of morbidly obese individuals who are most often recommended for a procedure. The system includes an endoscopically implanted tube and a port used by the patient to drain contents of the stomach and reduce calories absorbed.
You may also be interested in...
It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and, on the same day, Aspire Bariatrics reached a key milestone with the PMA submission for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.
Higher-risk devices, based on feasibility trial adverse event rates, would be matched to steeper effectiveness targets in pivotal studies for weight-loss under a plan outlined by the agency.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.